Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Infectious Disease

Articles with lock require a GLG News subscription
Posted May 30, 2007
Will AMO's contact lens solution problem be the same as Bausch and Lomb's?
Analysis of: CDC warns about contact lens solution | news.yahoo.com
Author: GLG Member Program Contributor
This article reports a contact lens associated infection with Advanced Medical Optics contact lens solution.  Despite owning less than 10% of the Market Share, AMO Complete® MoisturePlus™ (AMOCMP) multipurpose cleaning solution has been implicated in 60% of the cases of Acanthamoeba...
Posted May 30, 2007
Acanthamoeba keratitis
Analysis of: CDC warns about contact lens solution | news.yahoo.com
Author: GLG Member Program Contributor
No, this is an entirely different outbreak.  The formulation is clearly at fault.  The problem is not isolated with Complete Moisture Plus.
Posted May 15, 2007
Something new for Pandemic Flu
Analysis of: Focetria(R), the Novartis pandemic influenza vaccine, receives European Union approval | www.pipelinereview.com
Author: GLG Member Program Contributor
There is great concern in the field regarding the next pandemic flu strain. Prevention is key here. There is not enough medication to cover all suseptible individuals This new technology using the MF59 adjuvant should allow for enough vaccine to be available.
Glen McDaniel Posted May 9, 2007
Brokering a deal for HIV drugs is a big win
Analysis of: Clinton Says 66 Developing Nations To Get Cheaper AIDS Drugs | www.medicalnewstoday.com
Author: Glen McDaniel, President and Chief Executive Officer GM Global
The fact that this deal was successfully brokered is a victory for HIV patients, poor countries and the free market. As pharmaceutical companies compete to get market share and to win the PR war, they will enter into deals such as these more and more. This is one case in which everyone wins.
Posted May 9, 2007
Telbivudine is a new option for patients with hepatitis
Analysis of: Sebivo(R) (Telbivudine) Approved in European Union as a New Treatment for Chronic Hepatitis B Patients | www.pipelinereview.com
Author: GLG Member Program Contributor
Telbivudine is a new option of treatment for patients with chronic hepatitis B.In the United States, approximately 1.2 million persons have chronic hepatitis B virus (HBV) infection and are sources for HBV transmission to others. Two billion people infected worldwide, and 350 million suffering...
Posted May 9, 2007
Opening AIDS patents are the future for older drugs
Analysis of: Brazil Bypasses Patent on U.S. AIDS Drug | www.reuters.com
Author: GLG Member Program Contributor
Newer, more efficacious antiretrovirals are emerging.Older treatments  must be open in order to be competitive and continue in the market.
Posted April 30, 2007
Is it the disease or the therapy
Analysis of: HIV infection appears to increases the risk of heart attack | www.physorg.com
Author: GLG Member Program Contributor
This observational study shows that there is an increased incidence of heart disease in HIV patients. The question is -Is it the diseae or its therapy? In either case risk factor modification needs to be undertaken. More drugs? Where will the compliance go?
Posted April 30, 2007
AIDS and Heart Disease
Analysis of: HIV infection appears to increases the risk of heart attack | www.physorg.com
Author: GLG Member Program Contributor
Not the only study to indicate a relationship between HIV disease and cardiac disease. Supports other studies which also indicate increase in cardiovascular diseaseCardiovascular disease now a major cause of morbidity and mortality in AIDS patients
Posted April 30, 2007
Long Term Efficacy and Toxicity of Viral Entry Inhibitors Still Speculative
Analysis of: FDA To Consider Approval Of First CCR5 Antagonist Against HIV/AIDS | www.medicalnewstoday.com
Author: GLG Member Program Contributor
This is the first entry inhibitor to be addressed by the FDA but more are in pipeline.As entry inhibitors are a very new class of anti-virals, little is known about long term use.The CCR5 entry inhibitors will require pre-testing to see if the virus will potentially be susceptable (Pfizer has indicated...
Posted April 23, 2007
Merck and Gilead Compete on Integrase Inhibitors
Analysis of: New Class Of HIV Drug Attacks Previously Untargeted Enzyme | medicalnewstoday.com
Author: GLG Member Program Contributor
Although Merck's intergrase inhibitor(MK-0518 or raltegravir) is further ahead in the pipeline than Gilead's (GS-9137 or elvitegravir)they will both be significant contributions to HIV treatment. They should have low toxicity as this enzyme is not found in human cells and once that is shown, they...
Previous Page : 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next151 to 160 of 227

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T05:45:18.353